A Short Regimen for Rifampicin-resistant Isoniazid-susceptible TB

To assess outcome of treatment and safety among patients with rifampicin-resistant isoniazid-susceptible pulmonary tuberculosis treated with a novel regimen consisting of isoniazid, bedaquiline, and moxifloxacin throughout for 6 months, supplemented by pyrazinamide for the initial 2 months.

NCT Number	NCT06526039
Lead Sponsor	Taipei Medical University WanFang Hospital Collaborators: Hualien Tzu Chi General Hospital, Chest Hospital, Ministry of Health and Welfare, Taiwan, Chang-Hua Hospital, Taichung Veterans General Hospital, Taichung Hospital, Ministry of Health and Welfare, Taoyuan General Hospital, Kaohsiung Veterans General Hospital., Kaohsiung Medical University Chung-Ho Memorial Hospital
Conditions	Tuberculosis, Pulmonary
Enrollment	100 participants
Start Date	2024-07
Primary Completion	2028-12 (estimated)
Study Completion	2029-12 (estimated)
Updated on ClinicalTrials.gov	2024-07-29